Single shot epidural in hemophiliac
Factor 8 hemophiliac referred for lesi by his neurosurgeon for radiculopathy. I am not inclined to do this in my outpatient fluoroscopy suite but curious as to appropriate protocol if i was to proceed. Would have his hemotologist provide written clearance, factoring and recs. Thanks
The article Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients, written by Pierre Chelle, Cindy H. T. Yeung, Santiago Bonanad, Juan Crist óbal Morales Muñoz, Margareth C. Ozelo, Juan Eduardo Megías Vericat, Alfonso Iorio, Jeffrey Spears, Roser Mir, Andrea Edginton, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 21 May 2019 without open access.
Achieving the goal of zero bleeds as patients pursue active lives will require divergent dosing, according to PROPEL trial investigators who evaluated whether more exposure to FVIII improves outcomes.Medscape Medical News
AbstractHaemophilia A (HA) is caused by a lack or reduced amount of factor VIII protein (FVIII). About one-third of patients with non-severe HA carrying specific missense mutations show discrepant results between FVIII activity (FVIII:C), measured by one-stage or chromogenic two-stage assays. The aim of this study was to elucidate the mechanism underlying the assay discrepancy in vitro and in silico. Thirteen missense mutations in theFactor 8-gene associated with discrepant results in patients were transiently expressed. FVIII:C of the mutations was determined using two one-stage assays (FVIII:C1st, FVIII:CBonn) and a two-...
Condition: Hemophilia A Interventions: Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi); Biological: Rurioctocog alfa pegol (Adynovi) Sponsor: Bayer Not yet recruiting
The race for new, long-lasting treatments for the two most common forms of hemophilia heated up this week as two local gene therapy companies presented trial data for drugs in development alongside Big Pharma players. Lexington biotech UniQure N.V. (Nasdaq: QURE) — which has been the subject of M&A rumors in recent weeks, per Bloomberg — presented new data earlier this week on its treatment for hemophilia B, a form of the rare, genetic blood disease which affects the body’s ability to form…
Abstract PMID: 31296582 [PubMed - as supplied by publisher]
Authors: Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C Abstract Introduction: Prophylaxis with factor replacement therapy is the gold standard for the treatment of hemophilia, but this often requires frequent infusions. A number of long-acting factor products have been developed to reduce the burden on patients. Areas covered: This is an overview of information presented at two symposia held at the World Federation of Hemophilia and International Society on Thrombosis and Haemostasis - Scientific and Standardization Committee annual meetings. The pharmacokinetic, safety a...
We report herein is such a rare case of acquired hemophilia in a patient with CLL.
SAN RAFAEL, Calif., July 9, 2019 -- (Healthcare Sales &Marketing Network) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and forme... Biopharmaceuticals, Personnel BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy
Roche today announced new data for Hemlibra ® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia.